Brief: ABVC Provides Oncology Pipeline Updates
22/08/2022 13:39
Aug 22 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC PROVIDES ONCOLOGY PIPELINE UPDATES
* ABVC BIOPHARMA INC - EXPECTS TO INITIATE FIRST PHASE II
CLINICAL
TRIALS FOR ABV-1703 IN Q2 OF 2023
* ABVC BIOPHARMA INC - SEES STUDIES FOR ABV-1519 FOR
NON-SMALL
CELL LUNG CANCER, ABV-1501 FOR TRIPLE NEGATIVE BREAST CANCER TO
BE INITIATED IN Q3 2023
* ABVC BIOPHARMA INC - CLINICAL STUDY FOR ABV-1702 FOR
MYELODYSPLASTIC SYNDROME IS EXPECTED TO START IN Q4 OF 2023
* ABVC BIOPHARMA INC - PLANS TO SUBMIT ABV-1703'S PHASE II
CLINICAL TRIAL IND TO TAIWAN FDA AFTER COMMENCING CLINICAL
TRIALS IN UNITED STATES
Source text for Eikon: ID:nGNX71yC0
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner